The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 17, 2017

Filed:

Sep. 17, 2013
Applicants:

Michael Patrick Dillon, Boston, MA (US);

Mika Lindvall, Oakland, CA (US);

Daniel Poon, Piedmont, CA (US);

Savithri Ramurthy, Arlington, MA (US);

Vivek Rauniyar, Cambridge, MA (US);

Cynthia Shafer, El Sobrante, CA (US);

Sharadha Subramanian, San Ramon, CA (US);

Huw Rowland Tanner, San Francisco, CA (US);

Inventors:

Michael Patrick Dillon, Boston, MA (US);

Mika Lindvall, Oakland, CA (US);

Daniel Poon, Piedmont, CA (US);

Savithri Ramurthy, Arlington, MA (US);

Vivek Rauniyar, Cambridge, MA (US);

Cynthia Shafer, El Sobrante, CA (US);

Sharadha Subramanian, San Ramon, CA (US);

Huw Rowland Tanner, San Francisco, CA (US);

Assignee:

Novartis AG, Basel, CH;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/519 (2006.01); C07D 239/70 (2006.01); C07D 487/04 (2006.01); C07D 207/36 (2006.01); A61K 31/527 (2006.01); A61K 45/06 (2006.01); C07D 487/10 (2006.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01); A61K 31/519 (2013.01); A61K 31/527 (2013.01); A61K 45/06 (2013.01); C07D 207/36 (2013.01); C07D 487/10 (2013.01);
Abstract

The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof; as further described herein. The present invention further provides pharmaceutical compositions comprising these compounds, and combinations comprising these compounds combined with or used with a therapeutic co-agent, as well as therapeutic uses of these compounds and compositions. These are useful in the treatment of diseases such as cancer that are associated with activation of ERK1 and/or ERK2, and especially for MAPK pathway dependent cancers showing resistance to Raf and/or MEK inhibitory cancer therapeutics.


Find Patent Forward Citations

Loading…